Molecular and Cellular Biochemistry

, Volume 250, Issue 1–2, pp 21–26 | Cite as

Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats

  • Nadeem Talpur
  • Bobby Echard
  • Debasis Bagchi
  • Manashi Bagchi
  • Harry G. Preuss
Article

Abstract

Pharmaceuticals such as finasteride and alpha blockers are used to treat symptoms of benign prostatic hyperplasia (BPH) and are known to cause severe adverse reactions. Accordingly, a search for safer, natural products has been undertaken. Two natural agents (nutraceuticals) have come under recent scrutiny; because natural products, in general, often have evidence of long-term safety. The present study compares the in vivo effects on androgen-induced prostatic enlargement in rats of two nutraceuticals – the widely recognized Saw Palmetto (Serenoa repens) and the less well-known Cernitin (defined pollen extract). Non-castrated rats, had a mean prostate weight of 124 mg ± 8.8 (S.E.M.) compared to the 24.5 mg ± 1.9 (S.E.M.) of the castrated rat followed under the same regimen (p < 0.01). When castrated rats were given testosterone, the mass increased significantly to 250.0 mg ± 31.7 (S.E.M.) (p < 0.01). In the five remaining groups, castrated rats receiving testosterone were given finasteride, an extract of Saw Palmetto, crushed whole berry derived from Saw Palmetto fruit, a water soluble and fat soluble extract of Cernitin or a combination of the Saw Palmetto extract and Cernitin. All treatments decreased the size of the prostate to roughly the same size as in the non-castrated rats, a size that was significantly smaller than castrated rats treated with testosterone in the same manner (p < 0.01). A second study examining non-castrated rats treated with very high doses of testosterone showed similar results. In both studies, the nutraceuticals generally decreased body weight. In conclusion, these studies show the ability of Saw Palmetto (whole berry and extract) and Cernitin to influence prostatic hyperplasia via effects on androgen metabolism.

benign prostatic hyperplasia (BPH) finasteride alpha blockers Saw Palmetto Cernitin androgen-induced prostatic hyperplasia castrated and non-castrated rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Preuss HG, Adderly B: The Prostate Cure. Crown Publishers, Inc., New York, 1998, pp 1-251Google Scholar
  2. 2.
    Lytton B, Emery JM, Harvard BM: The incidence of benign prostatic obstruction. J Urol 99: 639-645, 1968Google Scholar
  3. 3.
    Kortt MA, Bootman JL: The economics of benign prostatic hyperplasia treatment: A literature review. Clin Ther 18: 1227-1241, 1996Google Scholar
  4. 4.
    Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM: New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 155: 477-481, 1995Google Scholar
  5. 5.
    Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, Lundmo P, Pappas F, Round E, Shapiro D: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 22: 271-277, 1992Google Scholar
  6. 6.
    The Finasteride (MK-906) study group in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299, 1993Google Scholar
  7. 7.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 327: 1185-1191, 1992Google Scholar
  8. 8.
    Lepor H: Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 3(suppl): 75-84, 1990Google Scholar
  9. 9.
    Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474, 1992Google Scholar
  10. 10.
    Stenger A, Tarayre JP, Carilla E: Etude pharmacologique et biochimique de l'extrait hexanique de serenoa repens. B: Gaz Med de France 89: 2041-2048, 1982Google Scholar
  11. 11.
    Ebeling L: The therapeutic results of defined pollen extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. In: E. Schmiedt, J.E. Aiken, H.W. Bauer (eds). Therapy of Prostatitis. Zuckschwerdt Verlag, Munchen, 1986, pp 154-160Google Scholar
  12. 12.
    Leander G: A preliminary investigation on the therapeutic effect of Cernilton N in chronic prostatovesiculitis. Svenska Lakartidningen 59: 3296, 1962Google Scholar
  13. 13.
    Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B: Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition. Prostate 22: 43-51, 1993Google Scholar
  14. 14.
    Dunnett C: A multiple comparison procedure for comparing several treatments with control. J Am Stat Assoc 50: 1096-1121, 1955Google Scholar
  15. 15.
    Wise GJ, Md, EO: Hormonal treatment of patients with benign prostatic hyperplasia: Pros and cons. Curr Urol Rep 2: 285-291, 2001Google Scholar
  16. 16.
    Wilt TJ, Howe W, MacDonald R: Terazosin for treating symptomatic benign prostatic obstruction: A systematic review of efficacy and adverse effects. BJU Int 89: 214-225, 2002Google Scholar
  17. 17.
    Champault G, Patel JC, Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18: 461-462, 1984Google Scholar
  18. 18.
    Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29: 231-240, 1996Google Scholar
  19. 19.
    Plosker GL, Brogden RN: Serenoa repens (Permixon). A review of it pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9: 379-395, 1996Google Scholar
  20. 20.
    Denis LJ: Editorial review of ‘Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients.' The Prostate 29: 241-242, 1996Google Scholar
  21. 21.
    Braeckman J: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Curr Therap Res 56: 776-785, 1994Google Scholar
  22. 22.
    Yasumoto R, Kawanishi H, Tsujino T, Tsujita M, Nishisaka N, Horii A, Kishimoto T: Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther 17: 82-87, 1995Google Scholar
  23. 23.
    Becker H, Ebeling L: Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton N. Results of a placebo-controlled double-blind study. Urologe B 28: 301-306, 1988Google Scholar
  24. 24.
    Becker H, Ebeling L: Phytotherapy of BPH with Cernilton N. Result of a controlled clinical study. Urologe B 31: 113-116, 1991Google Scholar
  25. 25.
    Buck AC, Rees RW, Ebeling L: Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 64: 496-499, 1989Google Scholar
  26. 26.
    Buck AC, Cox R, Rees RW, Ebeling L, John A: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study. Br J Urol 66: 398-404, 1990Google Scholar
  27. 27.
    Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K: Clinical evaluation of Cernilton on benign prostatic hypertrophy — a multiple center double-blind study with Paraprost. Hinyokika Kiyo 36: 495-516, 1990Google Scholar
  28. 28.
    Inada T, Kitagawa T, Miyakawa M: Use of Cernilton in Patients with Prostatic Hypertrophy. Tobishi Pharmaceutical Co. Ltd., Tokyo, Japan, 1966Google Scholar
  29. 29.
    Brauer H: The treatment of benign prostatic hyperplasia with phytopharmacia: A comparative study of Cernilton and beta sitosterol. Therapeiwoche 36: 1686-1696, 1986Google Scholar
  30. 30.
    Rugendorff EW, Weidner W, Ebeling L, Buck AC: Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 71: 433-438, 1993Google Scholar
  31. 31.
    Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B: Inhibition of androgen metabolism and binding by a liposterolic extract of ‘serenoa repens B’ in human foreskin fibroblasts. J Steroid Biochem 20: 515-519, 1984Google Scholar
  32. 32.
    Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA: Randomized trial of a combination of natural products (cernitin, saw palmetto, β-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 33: 217-225, 2001Google Scholar
  33. 33.
    Kamijo T, Sato S, Kitamura T: Effect of cernitin pollen-extract on experimental non-bacterial prostatitis in rats. Prostate 49: 122-131, 2001Google Scholar
  34. 34.
    Loschen G, Ebeling L: Inhibition of arachidonic acid cascade by extract of rye pollen. Arzneimittelforschung 41: 162-167, 1991Google Scholar
  35. 35.
    Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H: Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lip-oxygenase metabolism. Arzneimittelforschung 42: 547-551, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Nadeem Talpur
    • 1
  • Bobby Echard
    • 1
  • Debasis Bagchi
    • 2
  • Manashi Bagchi
    • 2
  • Harry G. Preuss
    • 1
  1. 1.Department of PhysiologyGeorgetown University Medical CenterWashingtonUSA
  2. 2.School of Pharmacy and Health ProfessionsCreighton University Medical CenterOmahaUSA

Personalised recommendations